Astellas Wins FDA Nod for First-line Gastric Cancer Therapy
Here's How Much $100 Invested In Gilead Sciences 20 Years Ago Would Be Worth Today
Consumer, Labor Groups Urge FTC to Block Catalent Sale to Novo Nordisk - Report
Abbott Labs Path to Double-Digit Earnings Growth In 2025? This Analyst Is Optimistic
These Analysts Increase Their Forecasts On Abbott Laboratories After Better-Than-Expected Q3 Earnings
This Gilead Sciences Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday